Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers

被引：0

作者：

Leber, Andrew ^{[1
]}

Hontecillas, Raquel ^{[1
]}

Juni, Nuria Tubau ^{[1
]}

Bassaganya-Riera, Josep ^{[1
]}

机构：

[1] NIMML Inst, Blacksburg, VA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2337

引用

页码：4631 / 4632

页数：2

共 50 条

[21] Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study
Christoph Beglinger
Ke Hu
Ying Wang
Emmanuel Bouillaud
Christelle Darstein
Yanfeng Wang
Pharis Mohideen
Endocrine, 2012, 42 : 366 - 374
[22] Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study
Beglinger, Christoph
Hu, Ke
Wang, Ying
Bouillaud, Emmanuel
Darstein, Christelle
Wang, Yanfeng
Mohideen, Pharis
ENDOCRINE, 2012, 42 (02) : 366 - 374
[23] Glimepiride, a new once-daily sulfonylurea - A double-blind placebo-controlled study of NIDDM patients
Rosenstock, J
Samols, E
Muchmore, DB
Schneider, J
Abelove, WA
Asplin, CM
Bergstrom, RW
Berhanu, P
Borowski, GD
Browning, GV
Comstock, JP
Friedman, NM
Gollapudi, GM
Graber, AL
Guthrie, RA
Henson, BE
Hershon, KS
Krosnick, A
Levin, SR
Levy, P
Lock, JP
Lodewick, PA
Mersey, JH
Michie, DD
Mather, SR
Musey, VC
Palmer, JP
Peters, PJ
Poulos, JT
Prendergast, JJ
Reynolds, LR
Roberts, VL
Rosenblatt, S
Rosenthal, AR
Cavanaugh, JJ
Schneider, SH
Snyder, JW
Sweet, RA
Vestal, RE
DIABETES CARE, 1996, 19 (11) : 1194 - 1199
[24] Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers
Rocha, Jose-Francisco
Santos, Ana
Gama, Helena
Moser, Paul
Falcao, Amilcar
Pressman, Peter
Wallace Hayes, A.
Soares-da-Silva, Patricio
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (02) : 391 - 403
[25] A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers
Jansen, Mendel
Warrington, Steven
Dishy, Victor
Ohwada, Shoichi
Johnson, Lisa
Brown, Karen
Ishizuka, Hitoshi
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (06): : 661 - 669
[26] Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes:: A double-blind, placebo-controlled study
Scherbaum, WA
Göke, B
HORMONE AND METABOLIC RESEARCH, 2002, 34 (10) : 589 - 595
[27] Double-blind, placebo-controlled study of once-daily venlafaxine (XR) and fluoxetine in depressed outpatients
Rudolph, R
Aguiar, L
Entsuah, R
Derivan, A
PSYCHOPHARMACOLOGY BULLETIN, 1997, 33 (03) : 578 - 578
[28] Safety and tolerability of Ganoderma lucidum in healthy subjects:: A double-blind randomized placebo-controlled trial
Wicks, Sheila M.
Tong, Robin
Wang, Chong-Zhi
O'Connor, Michael
Karrison, Theodore
Li, Shang
Moss, Jonathan
Yuan, Chun-Su
AMERICAN JOURNAL OF CHINESE MEDICINE, 2007, 35 (03): : 407 - 414
[29] Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study
Irie, S.
Matsumura, Y.
Zdravkovic, M.
Jacobsen, L. V.
Kageyama, S.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2008, 46 (06) : 273 - 279
[30] Tolerability of indacaterol, a novel once-daily β2-agonist, in patients with asthma:: a randomized, placebo-controlled, 28-day safety study
Yang, William H.
Martinot, Jean Benoit
Pohunek, Petr
Beier, Jutta
Magula, Daniel
Cameron, Ray
Owen, Roger
Higgins, Mark
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 99 (06) : 555 - 561

← 1 2 3 4 5 →